表紙
市場調査レポート

世界の網膜静脈閉塞市場

Global Retinal Vein Occlusion Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 308874
出版日 ページ情報 英文 77 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
世界の網膜静脈閉塞市場 Global Retinal Vein Occlusion Market 2014-2018
出版日: 2014年07月23日 ページ情報: 英文 77 Pages
概要

網膜静脈閉塞は、網膜の血流が阻害され、眼の神経細胞が損傷し失明に至る場合もある疾患です。眼の静脈は非常に狭いため、静脈の血栓によって起こることがあります。高血圧や糖尿病、脂質異常症を患う人に起こりやすい疾患です。世界の網膜静脈閉塞市場は、今後2013〜2018年にかけCAGR16.04%で拡大するとみられています。

当レポートでは、世界の網膜静脈閉塞市場の将来の成長見通し、市場規模、ベンダー環境、ベンダーが直面する課題と市場で発生している主な動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 略語

第3章 当レポートの範囲

  • 市場概要
  • 製品概要

第4章 市場調査方法

第5章 イントロダクション

第6章 市場環境

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第7章 パイプラインポートフォリオ

第8章 発症率と罹患率

第9章 治療別市場セグメンテーション

  • 生物製剤
  • コルチコステロイド

第10章 投与ルート別市場セグメンテーション

  • 硝子体内
  • 血管内

第11章 投与形態別市場セグメンテーション

  • 溶液
  • インプラント

第12章 地域別セグメンテーション

第13章 購入基準

第14章 市場成長促進因子

第15章 促進因子とその影響

第16章 市場の課題

第17章 促進因子の影響と課題

第18章 市場動向

第19章 動向とその影響

第20章 ベンダー環境

  • 競合シナリオ
    • 主なニュース
    • 合併・買収
  • 市場シェア分析
  • その他の注目すべきベンダー

第21章 主要ベンダー分析

  • Bayer
  • Roche
  • Novartis
  • Regeneron Pharmaceuticals

第22章 このシリーズの他のレポート

図表

目次
Product Code: IRTNTR3864

About Retinal Vein Occlusion

Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.

TechNavio's analysts forecast the Global Retinal Vein Occlusion market will grow at a CAGR of 16.04 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Retinal Vein Occlusion market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of retinal vein occlusion.

TechNavio's report, the Global Retinal Vein Occlusion Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Retinal Vein Occlusion market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.

Other Prominent Vendors

  • Alimera Sciences
  • Bristol-Myers Squibb
  • NicOx
  • Santen Pharmaceutical Co.
  • Valeant Pharmaceuticals International

Key Market Driver

  • High Unmet Need

For a full, detailed list, view our report.

Key Market Challenge

  • Serious Adverse Side Effects

For a full, detailed list, view our report.

Key Market Trend

  • Introduction of Biologics

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • Product Portfolio

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Pipeline Portfolio

08. Rate of Incidence and Prevalence

09. Market Segmentation by Type of Therapy

  • 09.1.1. Biologics
  • 09.1.2. Corticosteroids

10. Market Segmentation by Route of Administration

  • 10.1.1. Intravitreal
  • 10.1.2. Intravenous

11. Market Segmentation by Dosage Forms

  • 11.1.1. Solutions
  • 11.1.2. Implant

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2013
    • 20.2.1. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Bayer
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation
    • 21.1.4. Business Segmentation by Revenue 2012 and 2013
    • 21.1.5. Sales by Geography
    • 21.1.6. Business Strategy
    • 21.1.7. Key Information
    • 21.1.8. SWOT Analysis
    • 21.1.9. Strengths
    • 21.1.10. Weaknesses
    • 21.1.11. Opportunities
    • 21.1.12. Threats
  • 21.2. Roche
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Business Strategy
    • 21.2.7. Key Information
    • 21.2.8. SWOT Analysis
    • 21.2.9. Strengths
    • 21.2.10. Weaknesses
    • 21.2.11. Opportunities
    • 21.2.12. Threats
  • 21.3. Novartis
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2013
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Sales by Geography
    • 21.3.6. Business Strategy
    • 21.3.7. Key Developments
    • 21.3.8. SWOT Analysis
    • 21.3.9. Strengths
    • 21.3.10. Weaknesses
    • 21.3.11. Opportunities
    • 21.3.12. Threats
  • 21.4. Regeneron Pharmaceuticals
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Product Segmentation
    • 21.4.4. Revenue Product Segmentation
    • 21.4.5. Business Strategy
    • 21.4.6. Key Information
    • 21.4.7. SWOT Analysis
    • 21.4.8. Strengths
    • 21.4.9. Weaknesses
    • 21.4.10. Opportunities
    • 21.4.11. Threats

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Retinal Vein Occlusion Market 2013-2018 (US$ million)
  • Exhibit 3: Pipeline Portfolio of the Drugs for the Treatment of Retinal Vein Occlusion
  • Exhibit 4: Global Retinal Vein Occlusion Market by Type of Therapy
  • Exhibit 5: Global Retinal Vein Occlusion Market by Route of Administration
  • Exhibit 6: Global Retinal Vein Occlusion Market by Dosage Forms
  • Exhibit 7: Global Retinal Vein Occlusion Market by Geographical Segmentation
  • Exhibit 8: Global Retinal Vein Occlusion Market Share Analysis 2013
  • Exhibit 9: Product-wise Revenue Share in Global Retinal Vein Occlusion Market 2013
  • Exhibit 10: Bayer AG: Business Segmentation 2013
  • Exhibit 11: Bayer AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 12: Bayer AG: Sales by Geography 2013
  • Exhibit 13: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 14: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 15: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 16: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 17: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 18: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: Novartis AG: Sales by Geography 2013
  • Exhibit 20: Regeneron Pharmaceuticals Inc.: Product Segmentation
  • Exhibit 21: Regeneron Pharmaceuticals Inc.: Revenue Product Segmentation 2013
Back to Top